Introduction {#section5-2040622320944777}
============

Psoriasis is one of the most common immune-mediated disorders. It involves the interaction between different immune cells and cytokines. Among these different players, TH17 cells are characterized by the production of cytokines, including interleukin (IL)-17A, and are regarded as key players in the pathogenesis of psoriasis. IL-17A acts on different cells, including keratinocytes, neutrophils, and endothelial cells, to stimulate the production of various chemokines and pro-inflammatory cytokines. Pro-inflammatory cytokines can then migrate into the systemic circulation, potentially resulting in endothelial dysfunction, formation of atherosclerotic plaques, and cardiovascular disease.^[@bibr1-2040622320944777]^ Therefore, psoriasis is also associated with accelerated atherosclerosis and increased risk of cardiovascular events.^[@bibr2-2040622320944777][@bibr3-2040622320944777][@bibr4-2040622320944777][@bibr5-2040622320944777]--[@bibr6-2040622320944777]^ Moreover, IL-17 is also a factor linking the pathogenesis of psoriasis with metabolic disorders and is associated with lipid metabolism, insulin resistance, and diet-induced obesity.^[@bibr7-2040622320944777]^ Metabolic syndrome also increases cardiovascular risk in the general population and is often associated with more severe forms of psoriasis.^[@bibr8-2040622320944777][@bibr9-2040622320944777]--[@bibr10-2040622320944777]^ Secukinumab is a fully human anti-IL-17A IgG1 monoclonal antibody for plaque psoriasis. However, reports of the effects of anti-IL-17A agents on metabolic parameters and cardiovascular risk are still limited. Therefore, our study aimed to determine the effects of secukinumab on metabolic parameters and obesity based on the disease activity and treatment response in patients with psoriasis.

Methods {#section6-2040622320944777}
=======

This study has been approved by the Institution Review Board of Chang Gung Memorial Hospital, Linkou branch (IRB no. 202000244B0). The IRB agreed to waive the informed consent because this research involves no more than minimal risk to patients and the waiver will not adversely affect the rights and welfare of the patients. A retrospective cohort study was carried out in Chang Gung Memorial Hospital, Linkou, between January 2016 and February 2020. Ninety-nine adult patients (⩾18 years old) were included in this study with the diagnosis of psoriasis for more than 1 year. Ninety-four patients had a diagnosis of moderate to severe psoriasis, which was defined as having a Psoriasis Area and Severity Index (PASI) score ⩾10 or ⩾10% of body surface area affected, that justified the use of secukinumab. Among them, 84 patients received 300 mg dose at weeks 0, 1, 2, 3 and 4 then once every 4 weeks from week 4 onward. Ten patients (10.1%) received 150 mg dose due to their lighter weight (⩾60 kg). Secukinumab was administrated in five patients for the treatment of psoriatic arthritis with 150 mg dose at weeks 0, 1, 2, 3 and 4 and once every 4 weeks thereafter. Patients receiving concomitant phototherapy or concomitant systemic treatments such as methotrexate, cyclosporin, acitretin, or other biologic agents were also excluded. The presence of psoriatic arthritis was not an exclusion criterion.

The disease activity was assessed using the PASI at baseline (week 0) and week 12 and 24. The body mass index (BMI), body weight (BW), acute phase reactants \[erythrocyte sedimentation rate (ESR), high-sensitivity C-reactive protein (hs-CRP)\], fasting glucose, and serum lipoprotein concentrations including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (TGs), were recorded at week 0, week 12 and week 24. Lipid protein ratios reflecting cardiovascular risk (Atherogenic Index of Plasma (AIP), defined as log(TG/HDL), were calculated. The correlation between changes in metabolic parameters and disease activity (PASI score, ESR, and hs-CRP) between week 0 and week 24 were assessed. The changes of metabolic parameters at week 0 and at intermediate timepoint (week 12) were also evaluated and were also stratified according to PASI-90 response at week 12 ([Supplemental Material Table S1](https://journals.sagepub.com/doi/suppl/10.1177/2040622320944777) online) or week 24 respectively. Subsequently, we compared the differences in metabolic parameters and lipoprotein ratios in PASI-90 responders at week 24 \[defined as PASI score with ⩾90% improvement (PASI-90+)\] *versus* PASI-90 non-responders at week 24 \[defined as PASI score with \<90% improvement (PASI-90--)\].

Categorical variables were assessed using the chi-square test. Quantitative variables at baseline (week 0) were analyzed using Student's *t*-test. The paired *t*-test was used to analyze metabolic parameters in patients before and after treatment. Because hs-CRP and ESR had a skewed distribution, the Wilcoxon signed rank test was used to analyze the ESR and hs-CRP in patients before and after treatment. Mann--Whitney *U* test was performed to analyze the ESR and hs-CRP at weeks 0, 12 and 24 between PASI-90+ and PASI-90--. A *p*-value less than 0.05 was considered significant. All statistical analyses were performed using SPSS v.25.0 (IBM, New York, USA).

Results {#section7-2040622320944777}
=======

The demographic characteristics of the subjects at baseline are described in [Table 1](#table1-2040622320944777){ref-type="table"}. The mean age at treatment was 44.73 years, with an average disease duration of 17.19 years, and 75.8% of patients were men. More than 80% of patients were overweight (BMI \>24 kg/m^2^) and almost 40% were obese (BMI \>30 kg/m^2^). The baseline age, disease activity, and comorbidities were similar in PASI-90+ and PASI-90--; however, PASI-90-- had longer disease duration, higher BW, lower proportion of biologic treatment-naïve patients, and a larger proportion of men. PASI-90-- tended to have higher baseline hs-CRP and uric acid levels compared with those in PASI-90+ ([Table 2](#table2-2040622320944777){ref-type="table"}).

###### 

Demographic and clinical characteristics of 99 psoriatic patients receiving interleukin-17A blockade (secukinumab/Cosentyx^®^).

![](10.1177_2040622320944777-table1)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                  All\             PASI-90+\        PASI-90--\       *p*
                                                                                  *N* = 99         *n* = 39         *n* = 60         
  ------------------------------------------------------------------------------- ---------------- ---------------- ---------------- ----------------------------------------------------------------
  Age^[†](#table-fn1-2040622320944777){ref-type="table-fn"}^, mean (±SD), years   44.73 (±13.15)   43.56 (±13.46)   45.48 (±13.00)   0.481

  Disease duration, years                                                         17.19 (±8.83)    14.82 (±8.65)    18.73 (±8.67)    0.031[\*](#table-fn2-2040622320944777){ref-type="table-fn"}

  Sex                                                                                                                                

   Male                                                                           75 (75.8)        24 (61.5)        51 (85.0)        0.015[\*](#table-fn2-2040622320944777){ref-type="table-fn"}

   Female                                                                         24 (24.2)        15 (38.5)        9 (15.0)         

  BW, kg                                                                          80.33 (18.07)    74.40 (14.23)    84.18 (19.33)    0.008[\*](#table-fn2-2040622320944777){ref-type="table-fn"}

  BMI, mean (±SD), kg/m^2^                                                        28.92 (±5.783)   27.24 (±4.73)    30.00 (±6.25)    0.021[\*](#table-fn2-2040622320944777){ref-type="table-fn"}

   \<24                                                                           18 (18.2%)       12 (30.8%)       6 (10.0%)        

   24--27                                                                         23 (23.2%)       8 (20.5%)        15 (25.0%)       

   27--30                                                                         19 (19.2%)       7 (17.9%)        12 (20.0%)       

   \>30                                                                           39 (39.4%)       12 (30.8%)       27 (45.0%)       

  Systemic agents-naive                                                           68 (68.7%)       22 (56.4%)       46 (76.7%)       0.046[\*](#table-fn2-2040622320944777){ref-type="table-fn"}

  Biologics-naïve                                                                 45 (45.5%)       25 (64.1%)       20 (33.3%)       0.004[\*](#table-fn2-2040622320944777){ref-type="table-fn"}

  Baseline, week 0, PASI (±SD)                                                    19.21 (±11.09)   19.04 (±10.16)   19.31 (±11.74)   0.906

  PASI (±SD), week 12                                                             3.23 (±3.92)     1.05 (±2.08)     4.64 (±4.19)     \<0.0001[\*](#table-fn2-2040622320944777){ref-type="table-fn"}

  Treated, week 24, PASI (±SD)                                                    3.79 (±4.83)     0.35 (±0.67)     6.03 (±5.05)     \<0.0001[\*](#table-fn2-2040622320944777){ref-type="table-fn"}

  Current smoking                                                                                                                    

   No                                                                             49 (49.5)        24 (61.5)        25 (41.7)        0.066

   Yes                                                                            50 (50.5)        15 (438.5)       35 (58.3)        

  Current drinking                                                                                                                   

   No                                                                             57 (57.6)        26 (66.7)        31 (51.7)        0.152

   Yes                                                                            42 (42.4)        13 (33.3)        29 (48.3)        

  Hypertension                                                                                                                       

   No                                                                             59 (59.6)        26 (66.7)        33 (55.0)        0.297

   Yes                                                                            40 (40.4)        13 (33.3)        27 (45.0)        

  Diabetes                                                                                                                           

   No                                                                             73 (73.7)        33 (84.6)        40 (66.7)        0.062

   Yes                                                                            26 (26.3)        6 (15.4)         20 (33.3)        

  Dyslipidemia                                                                                                                       0.526

   No                                                                             61 (61.6)        26 (66.7)        35 (58.3)        

   Yes                                                                            38 (38.4)        13 (33.3)        25 (41.7)        

  Hyperuricemia                                                                                                                      

   No                                                                             59 (59.6)        26 (66.7)        33 (55.0)        0.297

   Yes                                                                            40 (40.4)        13 (33.3)        27 (45.0)        

  Psoriatic arthritis                                                                                                                

   No                                                                             53 (53.5)        22 (56.4)        31 (51.7)        0.684

   Yes                                                                            46 (46.5)        17 (43.6)        29 (48.3)        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Age at treatment.

*p* \< 0.05 was considered statistically significant.

AIP, Atherogenic Index of Plasma (AIP = log(triglyceride/high-density lipoprotein cholesterol); BMI, body mass index; BW, body weight; PASI, Psoriasis Area and Severity Index; SD, standard deviation.

###### 

Metabolic parameters between PASI-90+ and PASI-90-- groups after interleukin-17A blockade (secukinumab/Cosentyx^®^) at week 0, week 12 and week 24.

![](10.1177_2040622320944777-table2)

                           Week 0   Week 12   Week 24                                                                                                                                           
  ------------------------ -------- --------- ----------------------------------------------------------- ----- ------ ----------------------------------------------------------- ----- ------ -----------------------------------------------------------
  hs-CRP (median, mg/dl)   3.7      2.3       4.4[\*](#table-fn5-2040622320944777){ref-type="table-fn"}   2.2   1.7    3.0[\*](#table-fn5-2040622320944777){ref-type="table-fn"}   2.5   1.8    3.6[\*](#table-fn5-2040622320944777){ref-type="table-fn"}
  ESR (median, mm/h)       9        9         9                                                           7     7      8                                                           8     7      8
  Sugar (mean, mg/dl)      98       101       97                                                          103   102    104                                                         102   103    101
  UA (mean, mg/dl)         6.6      6.1       6.9[\*](#table-fn5-2040622320944777){ref-type="table-fn"}   6.3   5.9    6.5                                                         6.4   6.1    6.5
  HDL (mean, mg/dl)        44       46        43                                                          44    46     42                                                          44    47     43
  LDL (mean, mg/dl)        114      114       113                                                         115   113    115                                                         113   113    113
  CHOL (mean, mg/dl)       185      184       185                                                         188   187    189                                                         188   190    186
  TG (mean, mg/dl)         134      129       137                                                         152   138    160                                                         152   141    159
  n-HDL (mean, mg/dl)      141      140       142                                                         145   141    147                                                         144   144    144
  AIP (mean)               0.45     0.41      0.47                                                        0.5   0.42   0.54                                                        0.5   0.43   0.54

The independent *t*-test was used to analyze metabolic parameters between PASI-90+ and PASI-90-- at (1) week 0, (2) week 12 and (3) week 24. Mann--Whitney *U* test was used to analyze the ESR and hs-CRP between PASI-90+ and PASI-90-- at (1) week 0, (2) week 12 and (3) week 24.

*p* value was less than 0.05.

AIP, Atherogenic Index of Plasma (AIP = log(TG/HDL cholesterol); CHOL, cholesterol; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; n-HDL, non-high-density lipoprotein; PASI, Psoriasis Area and Severity Index; TG, triglyceride; UA, uric acid

Overall, PASI scores improved significantly over the study period from a mean value of 19.21 at week 0 to 3.79 at week 24. Fifty-three patients (53.5%) reached PASI-90 at week 12 while 39 patients (39.3%) reached PASI-90 at week 24. As shown in [Table 3](#table3-2040622320944777){ref-type="table"}, the mean BW and BMI increased significantly at week 12 and week 24. When the patients were stratified by obesity (BMI \>30kg/m^2^ or not), obese patients had a significantly higher mean PASI score at weeks 0, 12 and 24 than non-obese patients ([Supplemental Table S2](https://journals.sagepub.com/doi/suppl/10.1177/2040622320944777)).

###### 

Changes of metabolic parameters at week 12 and week 24 after interleukin-17A blockade (secukinumab/Cosentyx^®^) stratified by PASI-90 response at week 24.

![](10.1177_2040622320944777-table3)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Week        All\       PASI-90+ at week 24\                                           PASI-90-- at week 24\                                                                                                                                                                                                                                              
              *N* = 99   *n* = 39                                                       *n* = 60                                                                                                                                                                                                                                                           
  ----------- ---------- -------------------------------------------------------------- ------------------------------------------------------------- ------- ----------------------------------------------------------- ----------------------------------------------------------- ------- ------------------------------------------------------------ ------------------------------------------------------------
  BW          80.33      81.12[\*](#table-fn9-2040622320944777){ref-type="table-fn"}    81.32[\*](#table-fn9-2040622320944777){ref-type="table-fn"}   74.40   75.66                                                       75.76                                                       84.18   84.66                                                        84.94

  BMI         28.92      29.19[\*](#table-fn9-2040622320944777){ref-type="table-fn"}    29.27[\*](#table-fn9-2040622320944777){ref-type="table-fn"}   27.24   27.68                                                       27.87                                                       30.00   30.17                                                        30.26

  hs-CRP^+^   3.7        2.2[\*\*](#table-fn10-2040622320944777){ref-type="table-fn"}   2.5[\*](#table-fn9-2040622320944777){ref-type="table-fn"}     2.3     1.7[\*](#table-fn9-2040622320944777){ref-type="table-fn"}   1.8[\*](#table-fn9-2040622320944777){ref-type="table-fn"}   4.4     3.0[\*](#table-fn9-2040622320944777){ref-type="table-fn"}    3.6

  ESR^+^      9          7                                                              8                                                             9       7                                                           7                                                           9       8                                                            8

  Sugar       98         103[\*](#table-fn9-2040622320944777){ref-type="table-fn"}      102                                                           101     102                                                         103                                                         97      104[\*](#table-fn9-2040622320944777){ref-type="table-fn"}    101

  UA          6.6        6.3[\*](#table-fn9-2040622320944777){ref-type="table-fn"}      6.4[\*](#table-fn9-2040622320944777){ref-type="table-fn"}     6.1     5.9                                                         6.1                                                         6.9     6.5                                                          6.5[\*](#table-fn9-2040622320944777){ref-type="table-fn"}

  HDL         44         44                                                             44                                                            46      46                                                          47                                                          43      42                                                           43

  LDL         114        115                                                            113                                                           114     113                                                         113                                                         113     115                                                          113

  CHOL        185        188                                                            188                                                           184     187                                                         190                                                         185     189                                                          186

  TG          134        152[\*](#table-fn9-2040622320944777){ref-type="table-fn"}      152[\*](#table-fn9-2040622320944777){ref-type="table-fn"}     129     138                                                         141                                                         137     160[\*](#table-fn9-2040622320944777){ref-type="table-fn"}    159[\*](#table-fn9-2040622320944777){ref-type="table-fn"}

  n-HDL       141        145                                                            144                                                           140     141                                                         144                                                         142     147                                                          144

  AIP         0.45       0.50[\*](#table-fn9-2040622320944777){ref-type="table-fn"}     0.50[\*](#table-fn9-2040622320944777){ref-type="table-fn"}    0.41    0.42                                                        0.43                                                        0.47    0.54[\*](#table-fn9-2040622320944777){ref-type="table-fn"}   0.54[\*](#table-fn9-2040622320944777){ref-type="table-fn"}
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mean, ^+^median.

The paired *t*-test was used to analyze metabolic parameters (1) between week 0 and week 12, (2) between week 0 and week 24. Wilcoxon signed rank test was used to analyze the ESR and hs-CRP (1) between week 0 and week 12, (2) between week 0 and week 24.

*p* value was less than 0.05.

*p* value was less than 0.001.

AIP, Atherogenic index of plasma (AIP = log(TG/HDL cholesterol); BMI, body mass index; BW, Body weight; CHOL, cholesterol; ESR, erythrocyte sedimentation rate; HDL, high-density lipoprotein; hs-CRP, high-sensitivity C-reactive protein; LDL, low-density lipoprotein; n-HDL, non high-density lipoprotein; PASI, Psoriasis Area and Severity Index; TG, triglyceride; UA, uric acid

Compared with hs-CRP at week 0, hs-CRP levels declined significantly at week 12 and week 24 respectively, with a median value of 3.7 at week 0, 2.2 at week 12 and 2.5 at week 24. Compared with TG at week 0, TG levels significantly escalated from an average of 134 mg/dl to 152 mg/dl at week 12 and 152 mg/dl at week 24. Uric acid at week 24 (mean, 6.4 mg/dl) was significantly lower than that at baseline (mean, 6.6 mg/dl). The AIP increased significantly from 0.45 to 0.50 after 12 weeks and to 0.50 after 24 weeks of treatment.

When the patients were stratified by PASI-90 response at week 24, hs-CRP decreased significantly at week 12 in both PASI-90+ and PASI-90--; but at week 24, the decline of hs-CRP was still significant in PASI-90+ but not in PASI-90--. A significant increase in mean TG and AIP levels at week 12 and week 24 were noted after secukinumab treatment among PASI-90--, but similar increase was not present in PASI-90+ at week 12 and week 24.

We further investigated the predictors of serum TG level change between week 0 and week 24 among patients who did not take lipid-lowering agents by using multiple linear regression analyses. As shown in [Table 4](#table4-2040622320944777){ref-type="table"}, a higher baseline CRP level and PASI-90 non-response were significantly correlated with TG level elevation, whereas age, sex, BMI, smoking, and drinking were not.

###### 

Predictors of serum triglyceride level difference between week 0 and week 24 after interleukin-17 blockade (secukinumab/Cosentyx^®^).

![](10.1177_2040622320944777-table4)

                                          Estimate   Standard error   *p*
  --------------------------------------- ---------- ---------------- -------
  Age (years)                             0.118      0.597            0.843
  Sex (male *versus* female)              −7.659     18.413           0.679
  BMI (kg/m^2^)                           −0.283     1.328            0.832
  Biologics-naive (yes *versus* no)       −26.601    14.210           0.065
  Smoking (yes *versus* no)               −0.944     14.979           0.950
  Drinking (yes *versus* no)              10.026     16.076           0.535
  diabetes (yes *versus* no)              −31.084    17.927           0.087
  Dyslipidemia (yes *versus* no)          15.162     16.454           0.360
  Psoriatic arthritis (yes *versus* no)   14.662     13.459           0.280
  Uric acid at week 0 (mg/dl)             0.143      4.438            0.974
  hs-CRP at week 0 (mg/dl)                1.093      0.453            0.018
  PASI-90 (responder or non-responder)    −30.062    14.660           0.044

BMI, body mass index; hs-CRP, high-sensitivity C-reactive protein; PASI, Psoriasis Area and Severity Index.

Discussion {#section8-2040622320944777}
==========

This is the first real-world study to investigate the impact of secukinumab treatment on metabolic parameters in psoriasis patients. In this study, a significant improvement in disease activity was found after 24 weeks of secukinumab treatment. PASI-90+ had a shorter disease duration, fewer previous biologic or systemic treatments, lower mean BW/BMI, and tended to be female, which were partially in concordance with findings from previous studies.^[@bibr11-2040622320944777],[@bibr12-2040622320944777]^ Moreover, BW, BMI, and serum TG and AIP levels were significantly higher at week 24 of treatment. Among these parameters, the elevation of TGs and AIP were more conspicuous in PASI-90--. The subsequent multiple linear regression analysis revealed that serum TG elevation was associated with a higher baseline hs-CRP level and PASI-90--. These findings suggest that metabolic parameters need to be regularly monitored during secukinumab treatment.

As previous studies have reported, we observed a loss of efficacy in patients receiving secukinumab at week 24. Over a half of the patients reached PASI-90 at week 12 but less than 40% of patients reached PASI-90 at week 24. Besides, in the PASI-90-- group, hs-CRP level decreased significantly at week 12 but then escalated with the loss of its significance at week 24. One previous study revealed that about 20% of patients treated with secukinumab exhibited loss of efficacy at 24--32 weeks.^[@bibr13-2040622320944777]^ Jorge *et al.* reported that a quarter of patients who achieved PASI-75 or PGA 0/1 at week 12 stopped secukinumab treatment before week 52 because of lack of efficacy.^[@bibr14-2040622320944777]^ All these results showed a similar trend, that patients lost the efficacy during secukinumab treatment.

Obesity is strongly associated with psoriasis severity and several comorbidities, including psoriatic arthritis, increased hepatic steatosis and dysregulated lipid metabolism, non-alcoholic fatty liver disease and premature cardiovascular disease.^[@bibr15-2040622320944777],[@bibr16-2040622320944777]^ Obesity is also associated with a higher disease severity and a lower response to secukinumab. Megna *et al.* found that obese patients receiving secukinumab had a significantly higher mean PASI score at week 24 than non-obese patients.^[@bibr17-2040622320944777]^ Regarding the BW change after biologic use, significant weight gain and BMI change have been reported after anti-tumor necrosis factor-α (anti-TNF-α) treatment;^[@bibr18-2040622320944777]^ however, the evidence regarding weight change in patients receiving secukinumab treatment was controversial. Recent studies, including one meta-analysis, showed there was no significant weight gain or increase in BMI among patients receiving IL-17 inhibitor treatment.^[@bibr19-2040622320944777]^ However, Gerdes *et al.* showed a weight decrease in patients treated with secukinumab for 52 weeks.^[@bibr20-2040622320944777]^ In contrast, our study found that BW and BMI increased after 24 weeks of secukinumab treatment. IL-17 has been shown to suppress adipogenesis through the combined effects of various transcriptional factors that regulate adipocyte differentiation.^[@bibr21-2040622320944777]^ IL-17 deficiency in mice generated diet-induced obesity and accelerated fatty tissue accumulation.^[@bibr22-2040622320944777]^ One recent study also found that food intake increases IL-17 in human blood, and IL-17 promotes a rapid increase in hypothalamic anorexigenic  pro-opiomelanocortin (POMC) neuron expression and reduces food intake in mice.^[@bibr23-2040622320944777]^ According to these observations, we may hypothesize that secukinumab may affect body weight by breaking the negative feedback loop of IL-17 in hypothalamus, and by interfering with adipogenesis in peripheral fat tissue. This may explain the weight gain in our patients since secukinumab inhibits the effects of IL-17. However, understanding the real relationship between IL-17 inhibitors and obesity in patients with psoriasis needs more prospective studies.

Furthermore, patients with psoriasis were more likely to develop dyslipidemia, including hypertriglyceridemia and lower HDL levels.^[@bibr24-2040622320944777][@bibr25-2040622320944777]--[@bibr26-2040622320944777]^ Altered adipokines may drive disturbance of lipid metabolism in patients with psoriasis.^[@bibr27-2040622320944777]^ In the murine model, anti-IL-17A antibody led to an unchanged TG level but significantly reduced HDL and cholesterol levels.^[@bibr28-2040622320944777]^ Gerdes *et al.* demonstrated that secukinumab had a neutral effect on lipid parameters.^[@bibr20-2040622320944777]^ In the VIP-S study,^[@bibr29-2040622320944777]^ slight increases in total cholesterol and LDL were observed following secukinumab treatment, but no changes in inflammatory markers or TG levels were seen. Consistent with Gerdes' study, LDL, HDL, and total cholesterol levels remained unchanged in our study; however, the TG level increased significantly in PASI-90--, who had higher baseline hs-CRP levels than PASI-90+. On subsequent multiple linear regression analysis, elevation of serum TG strongly correlated with baseline hs-CRP levels and PASI-90-- status. The possible hypothesis of TG elevation is that systemic inflammation is actually responsible for TG elevation in PASI-90--. PASI-90-- had a higher hs-CRP at weeks 0, 12 and 24 than PASI-90+ ([Table 2](#table2-2040622320944777){ref-type="table"}), indicating that PASI-90-- may have a stronger systemic inflammation than PASI-90+ throughout the study period. Besides, there is a tendency for an increase in serum TG in patients with psoriasis, and psoriasis is also associated with the hypertriglyceridemia in a "dose-dependent" manner, which means that the severity of psoriasis correlates with hypertriglyceridemia, from 10% increase in the odds in those with mild psoriasis to 46% in those with severe psoriasis.^[@bibr8-2040622320944777]^ Therefore, sustained systemic inflammation in PASI-90--, instead of direct pharmacologic effect from secukinumab, may be really associated with an increase of TG levels in our study. TG levels are influenced by the inflammatory status of a subject; one study in Taiwanese showed that people with some specific apolipoprotein genotypes with low baseline CRP levels had significantly lower TG levels.^[@bibr30-2040622320944777]^ Besides, psoriasis involves cytokines such as tumor necrosis factor-α, IL-1, and IL-6, all of which can cause an increase in hepatic very low density lipoprotein production/secretion and an increase in plasma TG.^[@bibr31-2040622320944777]^ This should act as a reminder to physicians to monitor TG levels in patients (particularly PASI-90--) receiving secukinumab, and adequate control with lipid-lowering agents might be necessary.

Thus far, studies of the relationship between IL-17 and cardiovascular diseases have produced inconsistent results. IL-17 can exhibit proatherogenic and protective cardiovascular effects. One study showed that low serum levels of IL-17 were associated with a higher risk of major cardiovascular events in Caucasian patients with acute myocardial infarction, implying that IL-17 may play a cardioprotective role in patients with a history of cardiovascular events.^[@bibr32-2040622320944777]^ However, the IL-17A/IL-17RA axis increases aortic arch inflammation during atherogenesis.^[@bibr33-2040622320944777]^ One recent study suggested inhibition of IL-17A improved vascular and myocardial function compared with that following cyclosporine or methotrexate treatment by measuring left ventricular function using echocardiography.^[@bibr34-2040622320944777]^ More studies are needed to explore the effect of anti-IL-17A agents on cardiovascular diseases.

On the other hand, AIP is a useful tool to evaluate the risk of cardiovascular diseases.^[@bibr35-2040622320944777]^ AIP has been associated with heart failure, obesity and non-alcoholic fatty liver disease,^[@bibr36-2040622320944777][@bibr37-2040622320944777]--[@bibr38-2040622320944777]^ all of which belong to important comorbidities of psoriasis. One study on type 1 diabetes mellitus found an association between triglyceride-to-HDL ratio and hs-CRP level, and they hypothesize that elevated abnormal lipid profile would prompt the formation of foam cells in the arterial wall and increase the inflammatory activity.^[@bibr39-2040622320944777]^ Therefore, we infer that AIP may act as a marker to evaluate the cardio-metabolic risk in patients with psoriasis. In the present study, a high AIP value at baseline was presented in patients with psoriasis and significant elevation of AIP after secukinumab was noted in PASI-90--. Thus, we strongly suggest closer surveillance of cardiovascular disease in patients with psoriasis that show a poorer response to IL-17 inhibitor treatment.

This study has some limitations. First, we analyzed surrogate metabolic variables, such as BW, BMI, C-reactive protein, lipid profiles, and lipoprotein ratio in this study. Whether these parameters can serve as independent markers for an increased risk of cardiovascular events in patients receiving secukinumab remains uncertain. Second, there is a possibility that other confounding factors such as diet and exercise habit may affect the results. Third, the study was limited by its small sample size. In order to overcome these limitations and estimate changes in various metabolic variables during secukinumab treatment, a large-scale prospective study is needed. Last, as the control group, defined as patients receiving placebo for 24 weeks, is lacking in this study, the direct effect of IL-17 inhibitors on obesity and other metabolic parameters in psoriatic patients needs further study.

Our study highlights some important clinical implications. Longer disease duration, prior biologic or systemic agent use, and higher BW or BMI may be a hint for clinicians to predict an inferior response to secukinumab. PASI-90-- tended to have higher levels of systemic inflammation, presenting as higher hs-CRP and uric acid at baseline. Despite clinical improvement after secukinumab treatment, BMI and TG levels can still increase and may be risk factors for cardiovascular diseases. Furthermore, baseline hs-CRP and PASI-90 response are two predictive factors for the elevation of TG levels. BW and lipid-related variables should therefore be closely monitored in psoriasis patients receiving secukinumab treatment. Patients with psoriasis should be routinely screened for metabolic syndrome and treated appropriately to manage their cardio-metabolic risk.
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